Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Intrinsic Value
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases,... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of BHVN.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Biohaven Pharmaceutical Holding Company Ltd's business.
What risks and challenges
does Biohaven Pharmaceutical Holding Company Ltd face in the near future?
Summarize the latest earnings report
of Biohaven Pharmaceutical Holding Company Ltd.
Provide P/E
for Biohaven Pharmaceutical Holding Company Ltd and its competitors.
Balance Sheet Decomposition
Biohaven Pharmaceutical Holding Company Ltd
Current Assets | 442.4m |
Cash & Short-Term Investments | 381.8m |
Receivables | 13.6m |
Other Current Assets | 47m |
Non-Current Assets | 70.8m |
PP&E | 48.6m |
Intangibles | 19.8m |
Other Non-Current Assets | 2.4m |
Current Liabilities | 55.4m |
Accounts Payable | 15.6m |
Accrued Liabilities | 39.8m |
Non-Current Liabilities | 29.8m |
Other Non-Current Liabilities | 29.8m |
Earnings Waterfall
Biohaven Pharmaceutical Holding Company Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-436.1m
USD
|
Operating Income
|
-436.1m
USD
|
Other Expenses
|
27.9m
USD
|
Net Income
|
-408.2m
USD
|
Free Cash Flow Analysis
Biohaven Pharmaceutical Holding Company Ltd
What is Free Cash Flow?
BHVN Profitability Score
Profitability Due Diligence
Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Biohaven Pharmaceutical Holding Company Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BHVN Solvency Score
Solvency Due Diligence
Biohaven Pharmaceutical Holding Company Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Biohaven Pharmaceutical Holding Company Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BHVN Price Targets Summary
Biohaven Pharmaceutical Holding Company Ltd
According to Wall Street analysts, the average 1-year price target for BHVN is 60.69 USD with a low forecast of 55.55 USD and a high forecast of 69.3 USD.
Ownership
BHVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BHVN Price
Biohaven Pharmaceutical Holding Company Ltd
Average Annual Return | 84.93% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -25% |
Market Capitalization | 4.4B USD |
Shares Outstanding | 80 230 000 |
Percentage of Shares Shorted | 10.8% |
BHVN News
Last Important Events
Biohaven Pharmaceutical Holding Company Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Biohaven Pharmaceutical Holding Company Ltd
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. The company is headquartered in New Haven, Connecticut and currently employs 928 full-time employees. The company went IPO on 2017-05-04. The firm has a portfolio of therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. The firm's Neuroinnovation portfolio includes NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a pipeline of product candidates across five platforms: calcitonin gene related peptide (CGRP) receptor antagonism for the acute and preventive treatment of migraine as well as other pain-related disorders and non-migraine indications; glutamate modulation for obsessive-compulsive disorder (OCD); myeloperoxidase (MPO) inhibition for multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS); Kv7 Ion Channel Activators (Kv7) to target indications including epilepsy, pain disorders and effective disorders; and Myostatin offers a natural protein that limits skeletal muscle growth.